ICYMI, this week we had stories about dermatologic disparities among veterans and LGBTQIA+ patients, pediatric melanoma, a European approval for hidradenitis suppurativa, and more.
This Memorial Day, the Dermatology Times® team is taking the time to spotlight dermatologic disparities and concerns among veterans and active members of the military.
In this month’s Legal Eagle column, we delve into cases involving informed consent.
Learn more about the in-depth topics covered in the May 2023 issue of Dermatology Times®.
Click here to answer this week's poll.
This week's edition of the Mainstream Patient features stories about 8 Black-owned holistic beauty brands, tear trough filler for under-eye bags, dermatologist-approved SPF-containing moisturizers, and more.
Cryoanesthesia was safe and reduced pain in patients receiving intralesional triamcinolone steroid injections.
Researchers conducted a systematic review of pediatric melanoma.
In part 4 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.
Cameron Dermatology, which just opened in NYC, will address both medical and cosmetic issues.
In this week’s Pointers with Portela, the 208SkinDoc explains his recommendations for effective products to buy to start a skin care routine.
Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of May.
The phase 3b trial showed improvements to minimal disease activity in adults with the condition.
A public exhibition spotlighting individuals with birthmarks improved participants’ wellbeing and sense of self image.
As senior director, Del Rosso is looking forward to presenting numerous sessions and welcoming attendees to Orlando.
Apremilast is being examined for the treatment of psoriatic arthritis.
As Pride Month begins, the Dermatology Times® team wants to uplift LGBTQIA+ clinicians, patients, and topics in dermatology.
The approval makes the drug Europe’s first and only IL-17A inhibitor approved for the condition.
Scientists have found a new therapy for the severe inflammatory skin disorder.
The World Health Organization shared its enthusiasm for the “appropriate” use of these technologies. However, they are calling for caution to be exercised to protect and promote human well-being, safety, and autonomy and preserve public health.
Researchers examined the disease while going beyond current diagnostic tools.